Truist Securities Maintains Hold on Treace Medical Concepts, Raises Price Target to $5
Truist Securities analyst Richard Newitter maintains Treace Medical Concepts (NASDAQ:TMCI) with a Hold and raises the price target from $4 to $5.
Stocks · News reference
Treace Medical Concepts Raises FY2026 Sales Guidance from $202.000M-$212.000M to $204.000M-$212.000M vs $206.220M Est
Treace Medical Concepts (NASDAQ:TMCI) raises FY2026 sales outlook from $202.000 million-$212.000 million to $204.000 million-$212.000 million vs $206.220 million estimate.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Treace Medical Concepts shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance.
8-K filing — TREACE MEDICAL CONCEPTS, INC. (TMCI)
Filed: 2026-08-07 AccNo: 0001630627-26-000017 Size: 726 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Treace Medical Concepts Q2 EPS $(0.24) Beats $(0.30) Estimate, Sales $45.376M Beat $44.020M Estimate
Treace Medical Concepts (NASDAQ:TMCI) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.30) by 20 percent. This is a 14.29 percent increase over losses of $(0.28) per share